These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 35706397)

  • 21. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model.
    Guo W; Zhang Y; Chen T; Wang Y; Xue J; Zhang Y; Xiao W; Mo X; Lu Y
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):65-72. PubMed ID: 20336315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.
    Yuan S; Qiao T; Zhuang X; Chen W; Xing N; Zhang Q
    Yonsei Med J; 2016 Nov; 57(6):1312-23. PubMed ID: 27593857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non‑coding RNA BCYRN1 promotes glycolysis and tumor progression by regulating the miR‑149/PKM2 axis in non‑small‑cell lung cancer.
    Lang N; Wang C; Zhao J; Shi F; Wu T; Cao H
    Mol Med Rep; 2020 Mar; 21(3):1509-1516. PubMed ID: 32016455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.
    Li W; Liu J; Zhao Y
    Mol Carcinog; 2014 May; 53(5):403-12. PubMed ID: 23255458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
    PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and biological evaluation of novel modified dual-target shikonin derivatives for colorectal cancer treatment.
    Ma Y; Lai X; Wen Z; Zhou Z; Yang M; Chen Q; Wang X; Mei F; Yang L; Yin T; Sun S; Lu G; Qi J; Lin H; Han H; Yang Y
    Bioorg Chem; 2023 Oct; 139():106703. PubMed ID: 37399615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
    Shao N; Song L; Sun X
    Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo.
    Meng MB; Wang HH; Guo WH; Wu ZQ; Zeng XL; Zaorsky NG; Shi HS; Qian D; Niu ZM; Jiang B; Zhao LJ; Yuan ZY; Wang P
    Cancer Lett; 2015 Jan; 356(2 Pt B):985-93. PubMed ID: 25444918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2.
    Shankar Babu M; Mahanta S; Lakhter AJ; Hato T; Paul S; Naidu SR
    PLoS One; 2018; 13(2):e0191419. PubMed ID: 29394289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
    Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
    Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor M2-PK: A novel urine marker of bladder cancer.
    Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
    PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis.
    Dai ZQ; Gao F; Zhang ZJ; Lu MJ; Luo YJ; Zhang T; Shang BX; Gu YH; Zeng Q; Gao S; Guo ZQ; Xu B; Lei HM
    Phytomedicine; 2023 Aug; 117():154912. PubMed ID: 37295023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shikonin reactivates TSGs GADD45B and PPP3CC to block NSCLC cell proliferation and migration through JNK/P38/MAPK signaling pathways.
    Zhao Y; Wu D; Fu Z; Liu W; Yao Y; Liang Y
    BMC Complement Med Ther; 2024 Jan; 24(1):10. PubMed ID: 38167059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway.
    Wang H; Wu C; Wan S; Zhang H; Zhou S; Liu G
    Toxicology; 2013 Jun; 308():104-12. PubMed ID: 23562787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation.
    Pan Y; Wang W; Huang S; Ni W; Wei Z; Cao Y; Yu S; Jia Q; Wu Y; Chai C; Zheng Q; Zhang L; Wang A; Sun Z; Huang S; Wang S; Chen W; Lu Y
    J Cell Mol Med; 2019 Oct; 23(10):6846-6858. PubMed ID: 31343107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
    Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
    Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PKM2 inhibitor shikonin enhances piceatannol-induced apoptosis of glyoxalase I-dependent cancer cells.
    Inoue M; Nakagawa Y; Azuma M; Akahane H; Chimori R; Mano Y; Takasawa R
    Genes Cells; 2024 Jan; 29(1):52-62. PubMed ID: 37963646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation.
    Li W; Zhang C; Ren A; Li T; Jin R; Li G; Gu X; Shi R; Zhao Y
    PLoS One; 2015; 10(5):e0126459. PubMed ID: 25961580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis.
    Hua Q; Mi B; Xu F; Wen J; Zhao L; Liu J; Huang G
    Theranostics; 2020; 10(11):4762-4778. PubMed ID: 32308748
    [No Abstract]   [Full Text] [Related]  

  • 40. Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines.
    Thonsri U; Seubwai W; Waraasawapati S; Wongkham S; Boonmars T; Cha'on U; Wongkham C
    Anticancer Res; 2020 Sep; 40(9):5115-5124. PubMed ID: 32878800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.